1 HCMDSS Workshop PANEL 1: Design for Future Medical Devices November 16, 2004 Presentation by: Robert Kircher, Jr. Dose Safety Company P.O. Box 22865.

Slides:



Advertisements
Similar presentations
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Advertisements

The EMERALD RTD Plan and the ASAS Validation Framework R P (Bill) Booth 10 October 2002.
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Medical Device Software Development
BME-IDEA Workshop, September 28, 2005
Testing Medical Devices A Brief Overview © 2005 Max Cortner. Copying and distribution of this document is permitted in any medium, provided this notice.
The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.
Product Management & the FDA. Agenda/Scope What is different about managing products in a regulated industry? – Devices; Biologics; Pharma; Consumer goods;
The statements contained herein are based on good faith assumptions and provided for general information purposes only. These statements do not constitute.
Translational Medicine Turning Basic Research into Medicines and Treatments.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Slide 1 FAA’s Special Technical Audit of Boeing and the Audit Resolution Plan.
VARIAN Medical Systems Radiotherapy System Software Development Presented by Peter J Coronado 16 November 2004 at the Planning Meeting for the High Confidence.
Special Topics in IND Regulation
Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29,
CDRH Software Regulation
Software Verification and Validation (V&V) By Roger U. Fujii Presented by Donovan Faustino.
1.  An application describes the following proposed research activities: ◦ The investigator receives autopsy specimens from a pathologist. ◦ The investigator.
©Ian Sommerville 2004Software Engineering, 7th edition. Chapter 10 Slide 1 Critical Systems Specification 3 Formal Specification.
©Ian Sommerville 2004Software Engineering, 7th edition. Chapter 10 Slide 1 Formal Specification.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum 21 CFR Part 11 Considerations November 14, 2002.
An example of a critical system
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Effective Methods for Software and Systems Integration
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
MethodGXP The Solution for the Confusion.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Chapter 1- “Diversity” “In higher education they value diversity of everything except thought.” George Will.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Diabetes Past Present and Future Rich Hartmann 5/11/2010.
Working group 3: Patient Modeling and Simulation Ruzena Bajcsy—UC Berkeley Scott L. Bartow—Senatra Home Care Services Amit Bose—Tyco Healthcare M.Cenk.
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.
WXGE6103 Software Engineering Process and Practice Formal Specification.
Continuous Glucose Monitors
Model Checking and Model-Based Design Bruce H. Krogh Carnegie Mellon University.
Inclusion of Women in Clinical Trials & Drug Development Regulatory Perspective Ameeta Parekh, Ph.D. R&D Director Office of Women’s Health Food & Drug.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Health in Your Community Chapter 1 Section 3. Public Health  Practice of protecting and improving the health of people in a community.
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
| |
Integrated diabetes healthcare Frank Westermann CEO mySugr GmbH
Auditing ISO Nancy Pasquan November Introductions I am….. You are….. And we are here to discuss: Auditing ISO Quality Systems for Medical.
Progress Toward Artificial Pancreas (AP) Systems – A Timeline s 1980s : JDRF.
Medical Device Software Development
CompSci 280 S Introduction to Software Development
FDA's Two New Draft Guidance on Software and Device
The Working Group on Medical Measurements
Formal Specification.
Intelligent predictive artificial pancreas by biomimicry of the native beta cells – concept, prototype and the future Nils Kristian Skjærvold1,2,3, Anders.
U.S. FDA Center for Devices and Radiological Health Update
Clinical Research Contribution towards improving Clinical Care
Testbed for Medical Cyber-Physical Systems
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
EHR Integration Making Research Efficient
Preventing Medical Device Recalls
Mary Alexander, MA, RN, CRNI®, CAE, FAAN Chief Executive Officer
Software Myths Software is easy to change
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
US Early Feasibility Studies (EFS)
How open source is changing healthcare.
Combination products The paradigm shift
CABINET X-RAY MACHINE OPERATOR RADIATION SAFETY TRAINING COURSE
Ethical Considerations for Pediatric Clinical Investigations
Pharmaceuticals Industry
Presentation transcript:

1 HCMDSS Workshop PANEL 1: Design for Future Medical Devices November 16, 2004 Presentation by: Robert Kircher, Jr. Dose Safety Company P.O. Box Seattle, WA

2 About Dose Safety Company Formed in Early phase. Developing IDC (Insulin Dosing Controller) software for closed loop control of blood sugar for insulin- dependent diabetics. Artificial pancreas = IDC + insulin pump + sensor. Ongoing preliminary clinical trial. Started September Beginning to address regulatory process. PANEL 1: Design for Future Medical Devices Dose Safety Co., Seattle, WA

3 Safe and effective for its intended use Insulin pump BGL sensor By insulin pump mfgr. By Dose Safety The Future Challenge Insulin Dosing Controller (IDC)

4 Meeting the Challenge 1)Executable, PVS formal design specification and provable correct implementation of the IDC system which meets Safety and Efficacy Requirements (in work.) 2)Need: PVS libraries for infusion pumps, glucose sensors, infusion sets, etc. 3)Need: Formal Methods compliance with FDA regulation. 4)Need: High fidelity human subject simulation model. PANEL 1: Design for Future Medical Devices Dose Safety Co., Seattle, WA

5 2)Need: PVS libraries for infusion pumps, glucose sensors, infusion sets, etc. Customizable, building blocks required for the development and certification of medical device combinations. 3)Need: Formal Methods approach in compliance with FDA regulation. Tailor FM processes and artifacts as needed to comply with applicable regulation. Support development of new FDA guidance as necessary to minimize cert. efforts. Example: 21 CFR Part 820 Quality System Regulation, Subpart C Design Controls ( Google 21 CFR Part 820 ) 4)Need: High fidelity human subject simulation model Customizable model: gender, age, health, etc. Run real-time life scenarios: eat meals, get exercise. Use as plant model for closed-loop system development and test. Focus on areas that have most immediate benefit to public health and have the highest chances of success. Meeting the Challenge - details PANEL 1: Design for Future Medical Devices Dose Safety Co., Seattle, WA

6 Bio Robert C. Kircher, Jr. is the co-founder and managing partner of Dose Safety Company, for whom he developed software controller prototype and safety for a diabetes clinical trial being conducted. He worked twenty years for the Boeing Company supporting the requirements specification and validation testing of Boeing Commercial Airplane flight-critical systems, and accrued three US patents for digital navigation systems. Bob has published papers in peer-reviewed industry journals and has a B.A. in Mathematics from U.C. Berkeley and a Masters of Software Engineering from Seattle University.